Net sales of $631.1 million increased 5.7% year-over-yearIncome from operations of $140.2 million increased 6.1% year-over-yearNet income per diluted share of $2.47 increased 6.9%...
WESTFORD, Mass., July 28, 2025 /PRNewswire/ -- SkyQuest Technology Consulting published a report, titled, Data Center Market- Global Opportunity Analysis and Industry Forecast, 2025-2032",...
SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-12 (the “Reverse Stock Split”). The Company’s common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on August 5, 2025 under the existing symbol of “CLDI.” The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 320703 408.
"Advances in proteomics technologies are driving growth in precision medicine, with rising demand for early diagnostics, personalized therapies, and deeper insights into disease mechanisms."
BOSTON,...
"Advances in proteomics technologies are driving growth in precision medicine, with rising demand for early diagnostics, personalized therapies, and deeper insights into disease mechanisms."
BOSTON,...
As the Federal Reserve approaches its upcoming meeting, the dynamics between President Donald Trump and Fed Chair Jerome Powell have become notably strained. President...
The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...
The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...
The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...
The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...
COLUMBUS, Wis., July 24, 2025 (GLOBE NEWSWIRE) -- In a market update released today, Michael Eisenga, CEO of First American Properties LLC, addressed significant trends emerging in the U.S. housing sector for the month of June. Citing a confluence of weakening price trends, rising inventory, and a pullback in single-family home construction, Eisenga emphasized that the second half of 2025 may mark a structural shift in market dynamics—offering buyers more leverage than at any point in the past two years.
China has prioritized advancing its satellite capabilities to rival SpaceX's comprehensive Starlink network, which currently boasts nearly 8,000 low-Earth orbit (LEO) satellites. From a...
Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...
Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...